8-K: Elevance Health Reports Strong First Quarter 2024 Results, Raises Full-Year Guidance

Elevance Health's first quarter 2024 results show a 15.5% increase in diluted EPS and a raised full-year earnings outlook, driven by strategic initiatives and growth in Carelon.

Summary

• Elevance Health reported a 0.9% increase in operating revenue to $42.3 billion for the first quarter of 2024 compared to the same period last year.
• Diluted earnings per share (EPS) increased by 15.5% to $9.59, and adjusted diluted EPS rose by 12.5% to $10.64.
• The company has raised its full-year 2024 diluted EPS guidance to greater than $34.05 and adjusted diluted EPS guidance to greater than $37.20.
• Operating cash flow for the quarter was $2.0 billion, representing 0.9 times net income.
• Elevance Health repurchased 1.1 million shares of its common stock for $566 million during the quarter.
• Medical membership decreased by 1.9 million, or 4%, year-over-year, primarily due to Medicaid attrition.
• Carelon's operating revenue increased by 5% to $12.1 billion, driven by new risk-based capabilities and growth in CarelonRx.
• The company announced a strategic partnership with Clayton, Dubilier & Rice to advance primary care and physician enablement.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong earnings growth and raised guidance, although there are some concerns about membership attrition. The strategic partnership is a positive development.

Positives

• Elevance Health experienced a significant increase in diluted EPS and adjusted diluted EPS, indicating strong profitability.
• The company's full-year earnings guidance was raised, reflecting confidence in future performance.
• Carelon's revenue and operating gain showed strong growth, highlighting the success of its strategic initiatives.
• The company's share repurchase program and dividend payments demonstrate a commitment to returning value to shareholders.
• The strategic partnership with Clayton, Dubilier & Rice is expected to accelerate innovation in care delivery.

Negatives

• Medical membership decreased by 4%, primarily due to Medicaid attrition, which could impact future revenue.
• The operating expense ratio increased slightly due to investment and integration costs.
• Days in Claims Payable increased by 3.0 days compared to March 31, 2023, which could indicate potential cash flow challenges.

Risks

• The company faces risks related to healthcare cost trends, enrollment changes, and the ability to secure sufficient premium rates.
• Regulatory changes and compliance issues, particularly with Medicare and Medicaid programs, pose ongoing risks.
• Cybersecurity threats and data breaches could disrupt operations and lead to financial losses.
• Competitive pressures and the need to adapt to industry changes are significant challenges.
• The company's substantial debt and potential interest rate increases could impact its financial stability.

Future Outlook

Elevance Health has raised its full-year 2024 diluted EPS guidance to greater than $34.05 and adjusted diluted EPS guidance to greater than $37.20, reflecting a positive outlook for the remainder of the year.

Management Comments

• Gail K. Boudreaux, President and CEO, stated that the first quarter results reflect disciplined execution of strategic initiatives.
• Management highlighted the significant progress in expanding Carelon's capabilities and scaling the enterprise for growth.
• The strategic partnership with Clayton, Dubilier & Rice is expected to accelerate innovation in care delivery.

Industry Context

Elevance Health's results come during a dynamic period for the healthcare industry, with ongoing changes in regulations, cost pressures, and a focus on value-based care. The company's strategic initiatives and partnerships reflect a broader industry trend towards integrated care delivery and physician enablement.

Comparison to Industry Standards

• Elevance Health's 15.5% increase in diluted EPS is strong compared to peers in the managed healthcare sector, such as UnitedHealth Group (UNH) and Humana (HUM), which have also reported solid but not as high growth in recent quarters.
• The 0.9% increase in operating revenue is modest, but the growth in Carelon's revenue and operating gain is a positive sign, indicating successful diversification efforts.
• The 4% decrease in medical membership, primarily due to Medicaid attrition, is a concern, as other large players in the industry are also facing similar challenges due to eligibility redeterminations.
• The strategic partnership with Clayton, Dubilier & Rice is a unique move that could give Elevance Health a competitive edge in value-based care, setting it apart from competitors who are primarily focused on acquisitions or organic growth.

Stakeholder Impact

• Shareholders will benefit from increased earnings, share repurchases, and dividend payments.
• Customers may experience improved care delivery and health outcomes through the strategic partnership.
• Employees may see opportunities for growth and development as the company expands its capabilities.
• Suppliers and partners may benefit from increased business opportunities with Elevance Health.

Next Steps

• Elevance Health will continue to focus on expanding Carelon's capabilities and scaling its enterprise for growth.
• The company will work to implement its strategic partnership with Clayton, Dubilier & Rice.
• Management will host a conference call and webcast to discuss the first quarter results and outlook.

Key Dates

Keywords

Elevance Health, Healthcare, Earnings, EPS, Carelon, Medical Membership, Medicaid, Share Repurchase, Dividend, Operating Revenue